High-Frequency Stimulation of the Subthalamic Nucleus and l-3,4-Dihydroxyphenylalanine InhibitIn VivoSerotonin Release in the Prefrontal Cortex and Hippocampus in a Rat Model of Parkinson's Disease
Open Access
- 10 February 2010
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 30 (6), 2356-2364
- https://doi.org/10.1523/jneurosci.5031-09.2010
Abstract
High-frequency stimulation of the subthalamic nucleus (STN-HFS) andl-3,4-dihydroxyphenylalanine (l-DOPA) medication are the most used therapeutic approaches in Parkinson's disease (PD), but their beneficial motor effects are burdened by the emergence of cognitive and depressive disorders. Although a reduced serotonergic function has been linked to the psychiatric effects of antiparkinsonian treatments, biochemical evidence supporting this hypothesis is still lacking. By using a microdialysis approach in anesthetized rats, we investigated the ability of STN-HFS (130 Hz, 30 μA, 20 min) andl-DOPA (6–12 mg/kg) to change extracellular levels of serotonin (5-HT) monitored simultaneously in the prefrontal cortex (PFC) and hippocampus (HIPP), two brain regions involved in the regulation of mood and cognition that receive a distinct 5-HT innervation. The results show that STN-HFS inhibited 5-HT levels in the PFC and HIPP of sham-lesioned and 6-hydroxydopamine (6-OHDA)-lesioned rats. The effect elicited by STN-HFS was blocked by the administration of the 5-HT1Aagonist 8-hydroxy-N,N-dipropyl-2-aminotetralin.l-DOPA (6 and 12 mg/kg) reduced 5-HT levels in the PFC and HIPP of 6-OHDA rats. STN-HFS did not further decrease 5-HT levels induced byl-DOPA, but attenuatedl-DOPA-induced dopamine release in the PFC and HIPP. These neurochemical data show that STN-HFS inhibits 5-HT release by modulating serotonergic neuron activity, while the decrease in 5-HT levels induced byl-DOPA may include its direct action inside serotonergic neurons. These results support the premise that antiparkinsonian treatments reduce central serotonergic transmission, which may favor the development of nonmotor side effects in PD.Keywords
This publication has 57 references indexed in Scilit:
- Nonmotor Symptoms of Parkinson's Disease Revealed in an Animal Model with Reduced Monoamine Storage CapacityJournal of Neuroscience, 2009
- Behavioral Recovery in MPTP-Treated Monkeys: Neurochemical Mechanisms Studied by Intrastriatal MicrodialysisJournal of Neuroscience, 2008
- Levodopa: Past, Present, and FutureEuropean Neurology, 2008
- Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depressionBrain Structure and Function, 2008
- Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesionsInternational Journal of Neuropsychopharmacology, 2008
- Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleusProceedings of the National Academy of Sciences of the United States of America, 2007
- Preferential loss of serotonin markers in caudate versus putamen in Parkinson's diseaseBrain, 2007
- High‐frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l‐3,4‐dihydroxyphenylalanine in dopaminergic denervated ratsEuropean Journal of Neuroscience, 2007
- Transient Acute Depression Induced by High-Frequency Deep-Brain StimulationThe New England Journal of Medicine, 1999
- Variability among brain regions in the specificity of 6-hydroxydopamine (6-OHDA)-induced lesionsJournal of Neural Transmission, 1989